AKT1 and malignant colon neoplasm: Also, for colon cancer a tumor suppressing function was described where a reduced REST expression resulted in enhanced activity of the PI3K/AKT/mTOR signaling pathway, the target of Everolimus, a main therapeutic agent in siNET treatment55.